Current Report Filing (8-k)
June 02 2020 - 8:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 2, 2020
Menlo Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-38356
|
45-3757789
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification Number)
|
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
(Address of principal executive offices,
including Zip Code)
(800) 755-7936
(Registrant’s telephone number,
including area code)
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
|
MNLO
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01 Other Events.
On June 2, 2020, Menlo Therapeutics Inc. (the “Company”)
issued a press release announcing positive results from a Phase 2 clinical trial evaluating the preliminary safety and efficacy
of FCD105 (3% minocycline / 0.3% adapalene foam), the first ever topical minocycline-based combination product, for the treatment
of moderate-to-severe acne vulgaris. A copy of the press release is attached as Exhibit 99.1 to this report.
In addition, members of senior management of the Company
will be using the Investor Presentation attached as Exhibit 99.2 (the “Presentation”) to this report in
connection with providing a corporate overview at the Jefferies Virtual Healthcare Conference on June 2, 2020. The
Presentation is incorporated into this Item 8.01 by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are filed herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MENLO THERAPEUTICS INC.
|
|
|
|
Date: June 2, 2020
|
By:
|
/s/ Mutya Harsch
|
|
|
Mutya Harsch
|
|
|
Chief Legal Officer and General Counsel
|
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Menlo Therapeutics (NASDAQ:MNLO)
Historical Stock Chart
From Sep 2023 to Sep 2024